Press release
Immune Thrombocytopenia Market Size (7MM) was ~USD 1,870 Million in 2023 and is projected to grow at a significant CAGR by 2034, estimates DelveInsight
Unlock detailed insights into the Immune Thrombocytopenia Market by downloading the comprehensive report from DelveInsight @ Immune Thrombocytopenia Therapeutics Market [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Immune Thrombocytopenia Market Report
* In December 2025, Incyte Corporation initiated a Phase 2a study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
* In December 2025, Eli Lilly and Company conducted a study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it.
* In December 2025, Novartis Pharmaceuticals announced a study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count greater than or equal to 30 G/L in adult participants with primary ITP.
* In December 2025, argenx initiated a study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-label treatment period (OLTP1).
* In the 7MM, the US accounted for the highest number of Immune Thrombocytopenia Prevalence Cases with nearly 66,500 in 2023. These cases are expected to increase during the forecast period.
* Among the age-specific cases, the Immune Thrombocytopenia Prevalence among adults is much more than that among children.
* Among the gender-specific cases, there were nearly 20,600 Immune Thrombocytopenia diagnosed prevalence cases among males and nearly 35,000 cases among females in the US in 2023.
* Among EU4 and the UK, the UK accounted for the highest number of Immune Thrombocytopenia prevalence cases, followed by Germany. Whereas Spain occupied the bottom of the ladder.
* The leading Immune Thrombocytopenia Companies such as Rigel Pharmaceuticals, Kissei Pharmaceutical, Grifols, Sobi (Dova Pharmaceuticals), Asahi Kasei Pharma, Amgen, Argenx, Grifols (Biotest), Zenyaku Kogyo, Chugai Pharmaceutical, Novartis, Sanofi/Principia Biopharma, GC Pharma, UCB Biopharma, Takeda (Millennium Pharmaceuticals), Pfizer, Genosco and Oscotec, Vertex/Alpine Immune Sciences, Sanofi/ Bioverativ company , and others.
* Promising Immune Thrombocytopenia Pipeline Therapies such as Huaiqihuang Granule, Avatrombopag, BT595, Romiplostim, Hetrombopag, Rilzabrutinib, SKI-O-703, Eltrombopag, TQB3473 Tablets , and others.
Gain a competitive edge in the Immune Thrombocytopenia Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Immune Thrombocytopenia Treatment Drugs [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Immune Thrombocytopenia Epidemiology Segmentation in the 7MM
* Total Immune Thrombocytopenia Prevalent Cases
* Immune Thrombocytopenia Age-specific Diagnosed Prevalent Cases
* Immune Thrombocytopenia Gender-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Immune Thrombocytopenia Epidemiology Trends @ Immune Thrombocytopenia Prevalence [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Marketed Immune Thrombocytopenia Drugs
* TAVALISSE (fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical
Fostamatinib disodium (also known as TAVALISSE; R-985788) is an orally bioavailable investigational agent developed by Rigel Pharmaceuticals and approved for treating patients suffering from persistent/chronic adult idiopathic thrombocytopenic purpura. It inhibits FcR-triggered, SYK-dependent cytoskeletal rearrangement during phagocytosis. As stated by Rigel Pharmaceuticals, fostamatinib has a unique mechanism of action, blocking IgG receptor signaling in both macrophages and B cells via SYK kinase. It was approved by the US FDA in April 2018.
* DOPTELET (avatrombopag): Sobi (Dova Pharmaceuticals)
DOPTELET is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic Immune Thrombocytopenia who have had an insufficient response to previous treatment. In June 2019, the US FDA approved Dova Pharmaceuticals' supplemental New Drug Application (sNDA) for expanding DOPTELET use. The drug is indicated for the treatment of thrombocytopenia in adults with chronic Immune Thrombocytopenia who have had an insufficient response to a previous treatment.
Emerging Immune Thrombocytopenia Drugs
* Rilzabrutinib (PRN-1008): Sanofi/Principia Biopharma
Rilzabrutinib is an orally administered reversible covalent inhibitor of Bruton tyrosine kinase, a key player in signaling pathways downstream of the B-cell receptor (BCR) and Fc receptors. By blocking BTK activation, it regulates B-cell maturation and immune cell activation without depleting B-cells. This fast-acting therapy holds promise for treating autoimmune and inflammatory diseases. Rilzabrutinib is currently in the Phase III stage of development to treat Immune Thrombocytopenia in adults and adolescents with persistent or chronic Immune Thrombocytopenia. The company is anticipating the submission in 2024.
* Mezagitamab: Millennium Pharmaceuticals/Takeda
Mezagitamab is a subcutaneously administered human monoclonal antibody (human IgG1 lambda) that binds to the CD38 transmembrane glycoprotein expressed on the surface of cells and can deplete those cells by distinct mechanisms.
Discover key developments and opportunities in the Immune Thrombocytopenia Market. Click here to learn more from DelveInsight's latest report @ Immune Thrombocytopenia Market Size [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Immune Thrombocytopenia Companies
Rigel Pharmaceuticals, Kissei Pharmaceutical, Grifols, Sobi (Dova Pharmaceuticals), Asahi Kasei Pharma, Amgen, Argenx, Grifols (Biotest), Zenyaku Kogyo, Chugai Pharmaceutical, Novartis, Sanofi/Principia Biopharma, GC Pharma, UCB Biopharma, Takeda (Millennium Pharmaceuticals), Pfizer, Genosco and Oscotec, Vertex/Alpine Immune Sciences, Sanofi/ Bioverativ company , and others.
Immune Thrombocytopenia Market Outlook
The need to avoid the less effective immune suppressants has led to the development of new more targeted treatments for Immune Thrombocytopenia, starting with the second-generation TPO-RAs and now including SYK inhibition with other classes of treatment in clinical development. The introduction of these novel therapies has allowed to use of less immune suppression in Immune Thrombocytopenia management. Over the last decade, there has been a shift away from immune suppression for the treatment of Immune Thrombocytopenia.
Download DelveInsight's Immune Thrombocytopenia Market report today and stay ahead in this rapidly evolving field. @ Immune Thrombocytopenia Clinical Trials [https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Immune Thrombocytopenia Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Immune Thrombocytopenia Companies- Rigel Pharmaceuticals, Kissei Pharmaceutical, Grifols, Sobi (Dova Pharmaceuticals), Asahi Kasei Pharma, Amgen, Argenx, Grifols (Biotest), Zenyaku Kogyo, Chugai Pharmaceutical, Novartis, Sanofi/Principia Biopharma, GC Pharma, UCB Biopharma, Takeda (Millennium Pharmaceuticals), Pfizer, Genosco and Oscotec, Vertex/Alpine Immune Sciences, Sanofi/ Bioverativ company , and others.
* Immune Thrombocytopenia Pipeline Therapies- Huaiqihuang Granule, Avatrombopag, BT595, Romiplostim, Hetrombopag, Rilzabrutinib, SKI-O-703, Eltrombopag, TQB3473 Tablets , and others.
* Immune Thrombocytopenia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Immune Thrombocytopenia Unmet Needs, KOL's views, Analyst's views, Immune Thrombocytopenia Market Access and Reimbursement
Table of Contents
1. Key Insights
2. Immune Thrombocytopenia Market Report Introduction
3. Country-wise Immune Thrombocytopenia Market Overview at a Glance
4. Immune Thrombocytopenia Market Overview by Therapeutic Class
5. Methodology of Immune Thrombocytopenia Epidemiology and Market
6. Immune Thrombocytopenia Executive Summary
7. Key Events
8. Immune Thrombocytopenia Disease Background and Overview
9. Immune Thrombocytopenia Epidemiology and Patient Population
10. Immune Thrombocytopenia Patient Journey
11. Immune Thrombocytopenia Marketed Drugs
12. Immune Thrombocytopenia Emerging Drugs
13. Immune Thrombocytopenia: Market Analysis
14. Key Opinion Leaders' Views
15. Immune Thrombocytopenia SWOT Analysis
16. Immune Thrombocytopenia Unmet needs
17. Immune Thrombocytopenia Market Access and Reimbursement
18. Appendix
19. Immune Thrombocytopenia Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=immune-thrombocytopenia-market-size-7mm-was-usd-1870-million-in-2023-and-is-projected-to-grow-at-a-significant-cagr-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immune Thrombocytopenia Market Size (7MM) was ~USD 1,870 Million in 2023 and is projected to grow at a significant CAGR by 2034, estimates DelveInsight here
News-ID: 4336436 • Views: …
More Releases from ABNewswire
Peraso (NASDAQ: PRSO): The Digital Backbone of Robotaxi Fleets - Plus Tech Gamec …
This is where Peraso Technologies' (NASDAQ: PRSO) enters the picture.
Peraso specializes in 60 GHz mmWave wireless modules designed for ultra-high-speed, low-latency data transfer. In robotaxi environments, Peraso's technology enables multi-gigabit wireless offload, allowing vehicles to upload an entire day's worth of data in minutes rather than hours.
Key advantages include:
* Blazing-fast data transfer for AI training, diagnostics, and compliance
* Ultra-low latency supporting real-time vehicle-to-everything (V2X) communication
* Rapid, cost-effective deployment compared to…
Communication Platform as a Service Market: New Trends, Size, Share, Drivers, Gr …
Communication Platform as a Service Market by Component (Solutions (Message, Voice, Video) and Services (Professional and Managed)), Organization Size (SMEs and Large Enterprises), Vertical and Region - Global Forecast to 2027.
The global Communication Platform as a Service market [https://www.marketsandmarkets.com/Market-Reports/communications-platform-as-a-service-market-195778981.html?utm_campaign=communicationsplatformasaservicemarket&utm_source=abnewswire.com&utm_medium=referral] is expected to develop at a compound annual growth rate (CAGR) of 29.4%, from an estimated USD 12.5 billion in 2022 to USD 45.3 billion by 2027. One of the main…
Over the Top Market: Future Scope, New Trends, Demand Opportunities and Leading …
Over the Top Market by Type (Game Streaming, Audio Streaming, Video Streaming, and Communication), Monetization Model (Subscription-based, Advertising-based, and Transaction-based), Streaming Device, Vertical and Region - Global Forecast to 2027.
The size of the worldwide Over-The-Top (OTT) market [https://www.marketsandmarkets.com/Market-Reports/over-the-top-ott-market-41276741.html?utm_campaign=overthetopottmarket&utm_source=abnewswire.com&utm_medium=referral] is anticipated to increase at a Compound Annual Growth Rate (CAGR) of 16.5% from USD 202.5 billion in 2022 to USD 434.5 billion by 2027.
Without the use of any conventionally installed cable…
Beaza Unveils Innovation as a Premier Customized Face Cream Factory at Cosmoprof …
The global cosmetics and personal care industry is in the midst of a transformative shift, moving rapidly from mass-market offerings towards hyper-personalized consumer experiences. This trend is driven by sophisticated consumers who demand formulations tailored to their specific needs, skin types, and environmental factors. Against this backdrop of evolving demand, the need for agile, technologically advanced, and quality-focused manufacturing partners has never been more critical. The industry's pulse point, Cosmoprof…
More Releases for Immune
Immune Probiotic Supplement Market Reviews: What Works Best for Gut and Immune S …
The Global Immune Probiotic Supplement Market reached US$ 68.73 Billion in 2024 and is projected to witness lucrative growth by reaching up to US$ 133.08 Billion by 2032. The Global Immune Probiotic Supplement Market is expected to exhibit a CAGR of 8.61% during the forecast period 2024-2032.
Immune Probiotic Supplement Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges.…
Decoding the Immune System: Immune Repertoire Sequencing Market Unleashes Insigh …
The Immune Repertoire Sequencing Market is likely to grow voraciously, i.e. at a CAGR of 7.3% between 2018-2026. Augmented and virtual reality are abreast with advanced technologies on a significant count. VR and AR do have loads of potential for offering in the healthcare vertical. The application areas include surgery and training simulation, and patients care and treatment.
Persistence Market Research (PMR) delivers the key insights on the immune repertoire sequencing…
Immune health supplement Market - Guardian of health: Supporting immune strength …
Newark, New Castle, USA: The "Immune health supplement Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Immune health supplement Market: https://www.growthplusreports.com/report/immune-health-supplement-market/7978
This latest report researches the industry structure,…
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an…
Immune Health Supplements: Best Way to Boost Your Immune System
ResearchMoz include new market research report "Global Immune Health Supplements Market Research Report 2019" to its huge collection of research reports.
Immune Health Supplements refer to the product which could improve human immune health.
The global Immune Health Supplements market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
Learn more Through Sample Report…
